Also known as: peptide-based immunotherapies
Greenwich LifeSciences received a second Nasdaq notice for late filing of its Form 10-Q, following a prior notice for a late Form 10-K. The company's stock continues trading on the Nasdaq Capital Market while it works to file the overdue reports.
Sift Biosciences closed an oversubscribed $3.7 million pre-seed round to advance a peptide immunotherapy platform designed to activate pre-existing memory T cells. The financing will fund in vivo studies, expansion of its AI-powered discovery engine, and oncology lead selection.
Sift Biosciences, a UC Berkeley spinout, closed an oversubscribed $3.7 million pre-seed financing to advance its AI-driven peptide immunotherapy platform targeting immunologically "cold" solid tumors.
